Sylentis, S.A.
12
0
0
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
25%
3 trials in Phase 3/4
8%
1 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)
Role: lead
Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
Role: lead
Safety Study of Tivanisiran to Treat Dry Eye
Role: lead
Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops
Role: lead
SYL040012, Treatment for Open Angle Glaucoma
Role: lead
HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)
Role: lead
Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain
Role: lead
Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain
Role: lead
Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in Subjects With Ocular Hypertension or Open Angle Glaucoma
Role: lead
SYL040012. Tolerance and Effect on Intraocular Pressure in Subjects With Intraocular Pressure (IOP) >= 21 mm Hg
Role: lead
Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers
Role: lead
Tolerance and Effect on Intraocular Pressure After Administration of SYL040012
Role: lead
All 12 trials loaded